Noven to Present at Raymond James Institutional Investors Conference

MIAMI--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that Jeffrey F. Eisenberg, its Executive Vice President and Interim Chief Executive Officer, is scheduled to provide an update on Noven’s business and prospects at the Raymond James 29th Annual Institutional Investors Conference in Orlando on Monday, March 3, 2008, at 10:25 a.m. Eastern Time. The public is invited to listen to the presentation live via webcast at www.noven.com, and a replay will be available for at least two weeks at the same site.

About Noven

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Noven’s leading transdermal products utilize its proprietary DOT Matrix^® drug delivery technology and include Vivelle-Dot^® (estradiol transdermal system), the most prescribed estrogen patch in the U.S., and Daytrana™ (methylphenidate transdermal system), the first and only patch approved for the treatment of ADHD. Oral products currently offered through Noven’s psychiatry/CNS marketing and sales organization consist of Pexeva^® (paroxetine mesylate) and Lithobid^® (lithium carbonate). Developmental products in psychiatry consist of Stavzor™ (delayed release valproic acid capsule), Lithium QD (once-daily lithium carbonate), and Stavzor™ ER (extended release valproic acid capsule). Developmental products in women’s health consist of Mesafem™ (low-dose paroxetine mesylate), a non-hormonal product for vasomotor symptoms. See www.noven.com for additional information.